A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

NCT03281681 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Alternate study design for ovarian cancer under discussion

Conditions

Ovarian Cancer

Interventions

DRUG: VAL-083, Dianhydrogalactitol

Sponsor

DelMar Pharmaceuticals, Inc.